Objective: To determine the impact of prolonged storage of donor lungs at 10°C of up to 24h on outcome after lung transplantation.

Background: An increasing body of evidence suggests 10°C as the optimal storage temperature for donor lungs. A recent study showed that cold ischemic times can be safely expanded to >12h when lungs are stored at 10°C. However, it is currently unknown how long donor lungs can be preserved before they deteriorate in function.

Methods: Patients who received a donor lung stored at 10°C between 11/2020 and 06/2023 at the lung transplant programs of Toronto, Vienna and Madrid were included in this retrospective analysis. After excluding EVLP-cases, recipients were grouped based on the total preservation times of their donor organs (<12h: n=48; 12-18h: n=109; ≥18h: n=24). 372 recipients who had received an organ stored on-ice during the study period served as a control group.

Results: Length of lung preservation ranged from 2h 27min to 29h 33min (mean 14h 06min). Despite these prolonged preservation times, early postoperative outcomes were excellent. Median length of mechanical ventilation did not differ between the three study groups (<12h: 41h [IQR 24-109]; 12-18h: 56h [IQR 24-143] and ≥18h: 59h [IQR 28-108]; P=0.493). ICU length of stay (6 d [4-14]; 8 d [4-23]; 8 d [5-32]) and hospital length of stay (32 d [20-48]; 29 d [20-50]; 26 d [17-50]) were also similar. Furthermore, length of donor organ preservation had no impact on patient survival (log rank P=0.413).

Conclusions: Prolonged static preservation of donor lungs at 10°C for up to 24 hours is safe and does not impair short-intermediate outcomes after lung transplantation.

Download full-text PDF

Source
http://dx.doi.org/10.1097/SLA.0000000000006632DOI Listing

Publication Analysis

Top Keywords

donor lungs
12
stored 10°c
8
10°c
5
donor
5
prolonged preservation
4
preservation 24h
4
24h 10°c
4
10°c impact
4
impact outcomes
4
lung
4

Similar Publications

Airway basal stem cell therapy for lung diseases: an emerging regenerative medicine strategy.

Stem Cell Res Ther

January 2025

Department of Pulmonary and Critical Care Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

Chronic pulmonary diseases pose a prominent health threat globally owing to their intricate pathogenesis and lack of effective reversal therapies. Nowadays, lung transplantation stands out as a feasible treatment option for patients with end-stage lung disease. Unfortunately, the use of this this option is limited by donor organ shortage and severe immunological rejection reactions.

View Article and Find Full Text PDF

Scoliotic deformity represents a serious spinal disorder that influences the locomotive and cardiopulmonary systems. Some patients with severe scoliosis and end-stage lung disease are therefore denied lung transplantation. In patients with scoliosis considering lung transplantation, size match, straight back syndrome, delayed chest closure and bronchial stenosis are key issues clinicians should evaluate.

View Article and Find Full Text PDF

Fibrosis in PCLS: comparing TGF-β and fibrotic cocktail.

Respir Res

January 2025

Department for Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Introduction: Fibrotic cocktail (FC) is a combination of pro-fibrotic and pro-inflammatory mediators that induces early fibrotic changes in organotypic lung models. We hypothesised that transforming growth factor beta 1 (TGF-β1) alone induces a pro-fibrotic effect similar to FC. Our aim was to compare the pro-fibrotic effects of TGF-β1 with FC in human precision-cut lung slices (PCLS).

View Article and Find Full Text PDF

Cell therapy: A beacon of hope in the battle against pulmonary fibrosis.

FASEB J

January 2025

Stem Cell and Biotherapy Technology Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang, China.

Pulmonary fibrosis (PF) is a chronic and progressive interstitial lung disease characterized by abnormal activation of myofibroblasts and pathological remodeling of the extracellular matrix, with a poor prognosis and limited treatment options. Lung transplantation is currently the only approach that can extend the life expectancy of patients; however, its applicability is severely restricted due to donor shortages and patient-specific limitations. Therefore, the search for novel therapeutic strategies is imperative.

View Article and Find Full Text PDF

Burkholderia contaminans SK875, a member of Burkholderia cepacia complex (Bcc), are known to cause lung infections in cystic fibrosis patients. To gain deeper insights into its quorum sensing (QS)-mediated pathogenicity, we employed a transposon (Tn) insertion-based random mutagenesis approach. A Tn mutant library comprising of 15,000 transconjugants was generated through conjugation between wild-type (WT) recipient B.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!